Spyre Therapeutics, Inc.
SYRE
$75.77
$0.730.97%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Total Cash And Short-Term Investments | 741.47M | 756.53M | 486.20M | 526.58M | 564.82M |
| Total Receivables | 7.60M | 3.00M | 6.60M | 3.50M | 3.40M |
| Inventory | -- | -- | -- | -- | -- |
| Prepaid Expenses | 14.89M | 18.25M | 11.81M | 8.75M | 1.55M |
| Finance Division Loans and Leases Current | -- | -- | -- | -- | -- |
| Total Finance Division Other Current Assets | -- | -- | -- | -- | -- |
| Other Current Assets | -- | -- | -- | -- | -- |
| Total Current Assets | 763.95M | 777.78M | 504.60M | 538.83M | 569.77M |
|
|
|||||
| Total Current Assets | 763.95M | 777.78M | 504.60M | 538.83M | 569.77M |
| Net Property, Plant & Equipment | -- | -- | -- | -- | -- |
| Long-term Investments | -- | -- | -- | -- | -- |
| Goodwill | -- | -- | -- | -- | -- |
| Total Other Intangibles | -- | -- | -- | -- | -- |
| Finance Div Loans & Leases LT | -- | -- | -- | -- | -- |
| Total Finance Div Other LT Assets | -- | -- | -- | -- | -- |
| Total Other Assets | -- | -- | -- | -- | 10.00K |
| Total Assets | 763.95M | 777.78M | 504.60M | 538.83M | 569.78M |
|
|
|||||
| Total Accounts Payable | 5.69M | 8.90M | 7.46M | 3.71M | 3.69M |
| Total Accrued Expenses | 29.16M | 26.77M | 23.83M | 19.42M | 21.63M |
| Short-term Debt | -- | -- | -- | -- | -- |
| Current Portion of Long-Term Debt/Capital Leases | -- | -- | -- | -- | -- |
| Finance Division Debt Current | -- | -- | -- | -- | -- |
| Total Finance Division Other Current Liabilities | 50.31M | 23.01M | 14.99M | 59.93M | 45.36M |
| Total Other Current Liabilities | 50.31M | 23.01M | 14.99M | 59.93M | 45.36M |
| Total Current Liabilities | 85.16M | 58.69M | 46.27M | 83.06M | 70.68M |
|
|
|||||
| Total Current Liabilities | 85.16M | 58.69M | 46.27M | 83.06M | 70.68M |
| Long-Term Debt | -- | -- | -- | -- | -- |
| Short-term Debt | -- | -- | -- | -- | -- |
| Capital Leases | -- | -- | -- | -- | -- |
| Finance Division Debt Non Current | -- | -- | -- | -- | -- |
| Total Finance Division Other Non Current Liabilities | -- | -- | -- | -- | -- |
| Total Other Liabilities | 7.98M | 3.86M | 3.23M | -- | 16.49M |
| Total Liabilities | 93.14M | 62.55M | 49.50M | 83.06M | 87.17M |
|
|
|||||
| Common Stock & APIC | 1.71B | 1.69B | 1.36B | 1.35B | 1.34B |
| Retained Earnings | -1.20B | -1.13B | -1.07B | -1.05B | -1.02B |
| Treasury Stock & Other | -767.00K | 869.00K | 791.00K | 454.00K | 682.00K |
| Total Common Equity | 514.99M | 559.42M | 299.28M | 299.95M | 326.79M |
|
|
|||||
| Preferred Stock Redeemable | -- | -- | -- | -- | -- |
| Preferred Stock Non Redeemable | -- | -- | -- | -- | -- |
| Preferred Stock Convertible | 155.82M | 155.82M | 155.82M | 155.82M | 155.82M |
| Preferred Stock, Others | -- | -- | -- | -- | -- |
| Total Preferred Equity | 155.82M | 155.82M | 155.82M | 155.82M | 155.82M |
|
|
|||||
| Total Common Equity | 514.99M | 559.42M | 299.28M | 299.95M | 326.79M |
| Total Preferred Equity | 155.82M | 155.82M | 155.82M | 155.82M | 155.82M |
| Total Minority Interest | -- | -- | -- | -- | -- |
| Total Equity | 670.81M | 715.24M | 455.10M | 455.77M | 482.61M |
|
|
|||||